Specifically, the biosimilar, infliximab-abda, became the preferred anti-TNF therapy for the treatment of immune-mediated inflammatory disorders, including ulcerative colitis and Crohn’s disease at the Cleveland Clinic and affiliated hospitals and health centers. Here, TNF is linked to ulcerative colitis.